stockrow
Saturday 7 November 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
- Revenue
- −43.2%
- EPS
- −272.7%
- Free cash flow
- −184.7%
Quarter to June 2026, against a year earlier
30.77
0.34
+1.12%
Follow KRSA
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 2 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
(36.29) | (33.00) | — | (20.71) | (3.54) | (2.86) | (1.79) | — | — | — |
P/S ratio |
1.95 | 2.78 | — | 13.50 | 17.09 | 40.53 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(78.78) | (78.40) | — | (49.57) | (8.59) | (5.87) | (1.93) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(2.56) | 22.53 | — | (4.13) | (7.80) | (6.63) | (3.36) | — | — | — |
Beneish M-Score |
(1.95) | — | — | 11.62 | (3.95) | (4.16) | — | — | — | — |
P/B ratio |
0.44 | 0.92 | — | 2.79 | 1.40 | 1.56 | 0.76 | — | — | — |
Price to Tangible BV |
0.44 | 0.92 | — | 2.79 | 1.40 | 1.56 | 0.76 | — | — | — |
EV/Sales |
0.39 | 1.67 | — | 7.30 | 3.40 | 16.83 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.17 | — | — | — |
EV/Operating CF |
(0.24) | (1.13) | — | (0.39) | (0.37) | (0.53) | 0.20 | — | — | — |
EV/FCF |
(0.43) | (1.70) | — | (0.40) | (0.38) | (0.53) | 0.19 | — | — | — |
Quick Ratio |
4.71 | 5.22 | 3.63 | 1.77 | 4.88 | 3.22 | 5.28 | 0.00 | 0.00 | 0.00 |
Current Ratio |
5.15 | 5.83 | 3.85 | 1.94 | 5.00 | 3.45 | 5.55 | 0.05 | 0.09 | 0.03 |
Net Debt/EBITDA |
0.65 | 0.89 | 0.58 | 0.72 | 0.99 | 0.69 | 0.78 | 0.00 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.21 | 0.17 | 0.00 | 0.01 | 0.05 | 0.02 | 0.05 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.94 | 1.42 | 4.04 | 0.92 | 0.71 | 0.93 | 0.83 | 0.85 | 0.86 | 0.78 |
Capex/Depreciation |
— | — | — | 0.00 | 3.09 | 0.01 | (2.49) | (2.25) | (0.80) | 0.00 |
| (39.34%) | (30.36%) | (48.42%) | (150.19%) | (95.87%) | (98.97%) | (281.86%) | 1,212.41% | 1,225.50% | 829.25% | |
| (36.07%) | (26.64%) | (33.47%) | (113.88%) | (59.12%) | (51.55%) | (126.89%) | (1,790.88%) | (2,010.10%) | (1,360.17%) | |
ROIC |
(53.18%) | (40.36%) | (217.77%) | 0.00% | 0.00% | (996.29%) | (2,757.52%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(94.46%) | (87.34%) | (88.63%) | (612.79%) | (116.23%) | (160.70%) | (130.08%) | 1,100.78% | 1,086.18% | 940.01% |
Average Days of Receivables |
175.99 | 101.47 | — | 117.98 | 9.26 | 20.19 | 119.37 | — | — | — |
Research and Development Expense of Revenue |
46.24% | 14.30% | 0.00% | 2,013.13% | 954.74% | 2,457.06% | 2,110.94% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
293.54% | 267.10% | 0.00% | 4,329.29% | 523.08% | 1,255.05% | 763.35% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21.26% | 31.25% | 0.00% | 2,105.05% | 243.81% | 652.96% | 435.57% | 0.00% | 0.00% | — |
Graham Net Nets |
0.92 | 0.43 | — | 0.25 | 0.66 | 0.03 | 0.17 | — | — | — |
Graham Number |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(92.60%) | (37.88%) | — | (150.73%) | (78.07%) | (83.96%) | (165.22%) | — | — | — |
Free Cash Flow Yield |
(45.95%) | (35.46%) | — | (134.46%) | (52.06%) | (77.89%) | (146.25%) | — | — | — |
Revenue per Share |
4.56 | 5.56 | 0.00 | 0.96 | 14.09 | 10.57 | 23.04 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7.29) | (12.04) | (63.59) | (130.79) | (130.56) | (333.75) | (522.57) | (498.48) | (2.96) | (1.82) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 5.21 | 0.08 | (34.33) | (17.58) | (0.05) | 0.00 |
Free Cash Flow per Share |
(7.29) | (12.04) | (63.59) | (130.79) | (125.35) | (333.66) | (556.90) | (516.06) | (3.02) | (1.82) |
Cash per Share |
7.13 | 8.98 | 22.66 | 43.10 | 192.92 | 250.44 | 485.15 | 0.00 | 0.00 | 0.00 |
Shareholders Equity per Share |
19.98 | 24.60 | 33.79 | 33.66 | 172.49 | 273.91 | 499.64 | (53.40) | (0.31) | (0.25) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
19.98 | 24.60 | 33.79 | 33.66 | 172.49 | 273.91 | 499.64 | (53.40) | (0.31) | (0.25) |
Free Cash Flow |
(3.31) | (4.33) | (21.24) | (40.61) | (35.06) | (72.47) | (108.93) | (100.94) | (82.62) | (49.87) |
Working Capital |
3.74 | 3.50 | 5.94 | 7.19 | 44.37 | 41.55 | 82.95 | (16.97) | (12.78) | (10.36) |
Capital Expenditures |
— | — | — | — | 1.46 | 0.02 | (6.71) | (3.44) | (1.40) | (1.44) |
Net Current Asset Value |
3.74 | 3.50 | 5.94 | 7.19 | 44.37 | 2.62 | 12.45 | (16.97) | (12.78) | (10.36) |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.16 | — | — | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | (0.37) | (0.01) | 1.49 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | — | 0.00 | 7.26 | 0.33 | 0.23 | 0.24 | 0.42 | 0.60 |
Cash ROIC |
(26.89%) | (35.86%) | (112.65%) | (170.39%) | (34.30%) | (63.63%) | (56.55%) | 966.40% | 964.42% | 737.67% |
Accounts Receivable Turnover |
2.67 | 6.14 | — | 3.03 | 34.73 | 2.87 | 5.63 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.35 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 236.73 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.78 | 0.33 | — | 0.10 | 0.11 | 0.80 | 0.80 | — | — | — |
Average Payables |
0.45 | 0.79 | 2.08 | 2.40 | 1.63 | 2.37 | 3.05 | 2.29 | 1.61 | 1.61 |
Average Assets |
9.78 | 11.47 | 15.73 | 38.71 | 87.35 | 150.93 | 96.94 | 6.44 | 4.67 | 4.67 |
Average Common Equity |
8.97 | 10.07 | 10.87 | 29.35 | 53.87 | 78.61 | 43.64 | (9.51) | (7.66) | (7.66) |
Columns are period end dates · fundamentals updated 2 Nov 2026